Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab

J Am Acad Dermatol. 2023 May;88(5):1110-1111. doi: 10.1016/j.jaad.2019.05.070. Epub 2019 May 29.

Authors

Daniel Morgado-Carrasco¹, Macarena Giácaman-Von der Weth², Xavier Fustá-Novell¹, Sebastián Podlipnik¹, Amparo Pérez-Ferriols², Paula Aguilera³

Affiliations

¹ Dermatology Department, Photobiology Unit, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
² Dermatology Department, Hospital General Universitario de Valencia, Valencia, Spain.
³ Dermatology Department, Photobiology Unit, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain. Electronic address: aguilisha@hotmail.com.

PMID: 31150709
DOI: 10.1016/j.jaad.2019.05.070

No abstract available

MeSH terms

Anti-Allergic Agents* / therapeutic use
Chronic Disease
Follow-Up Studies
Humans
Omalizumab / therapeutic use
Treatment Outcome
Urticaria* / drug therapy
Urticaria* / etiology
Urticaria, Solar

Substances

Omalizumab
Anti-Allergic Agents